CD8A and leukemia: The relevance of allo-reactive CD8+ T cells in the control of leukemia has impressively been documented in leukemia patients receiving allogenic hematopoietic stem cell transplantation (aHSCT; refs. 6–8) or in patients receiving donor lymphocyte infusions after relapse (7, 9, 10).